OncoMatch/Clinical Trials/NCT07294677
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
Is NCT07294677 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for leukemia.
Treatment: Capivasertib · Venetoclax · Rituximab · Blinatumomab · Nelarabine · mini-hyperCVD — This is a 3-part study to assess the safety of adding capivasertib to a standard of care treatment regimen consisting of venetoclax and low-intensity chemotherapy. This chemotherapy regimen called mini-hyperCVD consists of the chemotherapy drugs, cyclophosphamide, vincristine, dexamethasone; (part A) alternating with high-dose methotrexate and cytarabine (part B) administered approximately every 28 days. In the first part of the study (Cohort 1), the study seeks to determine the recommended dose of capivasertib that can be safely given with venetoclax and chemotherapy. Several doses of capivasertib may be tested in small groups of subjects in this part of the study. The dose tested will be increased or lowered depending on types and frequency of side effects seen until the best, safe dose is found. Once the recommended, safe dose of capivasertib is found, the study will move on to the second part (Cohort 2) and will treat additional participants to learn more about the safety of giving these drugs together. If the combination is determined to be safe overall, the study will move on to the third part (Cohort 3). In this part of the study, participants will be randomized to receive the mini-hyperCVD and venetoclax alone or with capivasertib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic chemotherapy or radiotherapy for ALL/LBL
Exception: hydroxyurea, steroids, ATRA and/or intrathecal chemotherapy; no more than 2 weeks of steroids permitted
Any prior systemic chemotherapy or radiotherapy for treatment of ALL/LBL is an exclusion with the exception of hydroxyurea, steroids, ATRA and/or intrathecal chemotherapy. No more than 2 weeks of steroids is permitted.
Lab requirements
Blood counts
adequate organ function meeting protocol criteria
Kidney function
adequate organ function meeting protocol criteria
Liver function
adequate organ function meeting protocol criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify